Immunogen Inc $13.99

down -0.22


17/4/2014 08:10 PM  |  NASDAQ : IMGN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get IMGN Trend Analysis - it has underperformed the S&P 500 by 26%

Partner Headlines

  1. UPDATE: Canaccord Genuity Initiates Coverage on ImmunoGen Ahead of Phase ...

    Benzinga
  2. ImmunoGen Says Initial Research Shows New Dosing Approach for IMGN853 Achieves ...

    Benzinga
  3. IDEXX Laboratories Elects Daniel Junius to Board of Directors

    Benzinga
  4. US Stock Futures Down Ahead Of Wal-Mart Earnings, Economic Data

    Benzinga
  5. CytomX Therapeutics, ImmunoGen Announce Strategic Collaboration

    Benzinga
  6. ImmunoGen Announces Activity Reported with SAR3419 Plus Rituxan In Difficult-to-Treat ...

    Benzinga
  7. US Stock Futures Edge Lower Ahead Of FOMC Minutes, Economic Data

    Benzinga
  8. ImmunoGen Announces Approval of Roche's Kadcyla in EU

    Benzinga
  9. UPDATE: Morgan Stanley Downgrades ImmunoGen Following Phase 2 Failure of ...

    Benzinga
  10. Benzinga's Top #PreMarket Losers

    Benzinga
  11. ImmunoGen Announces License Agreement with Novartis

    Benzinga
  12. Mid-Afternoon Market Update: Marvell Rises on KKR Stake While Orbitz Gives ...

    Benzinga
  13. Mid-Day Market Update: BroadSoft Drops On Q3 Results; Endo Health Shares ...

    Benzinga
  14. Mid-Morning Market Update: Markets Open Lower; CVS Caremark Lifts Outlook

    Benzinga
  15. Benzinga's Top #PreMarket Losers

    Benzinga
  16. US Stock Futures Signal Lower Start On Wall Street

    Benzinga
  17. ImmunoGen Presents SAR566658 Clinical Findings at AACR-NCI-EORTC Conference ...

    Benzinga
  18. US Stock Futures Up; J.P. Morgan Earnings In Focus

    Benzinga
  19. ImmunoGen Announces New License Agreement with Novartis

    Benzinga
  20. ImmunoGen Announces Positive Results from Kadcyla Phase III Trial, TH3RESA ...

    Benzinga
  21. The 'L' In CANSLIM Stands For Leaders, Not Laggards

    IBD
  22. UPDATE: Oppenheimer Downgrades ImmunoGen to Perform on Valuation

    Benzinga
  23. Earnings Scheduled For January 25, 2013

    Benzinga
  24. From Earlier: Amgen Takes Third License for Rights to Use ImmunoGen's TAP ...

    Benzinga
  25. ImmunoGen Clinical Results of IMGN901

    Benzinga
  26. A Peek Into the Market Before the Trading Begins

    Benzinga
  27. ImmunoGen Announces Dr. Charles Morris as New Chief Development Officer

    Benzinga
  28. ImmunoGen Inc. Reports Operating Results (10-Q)

    GuruFocus
  29. It's All Bad News For ImmunoGen After 1Q13 Earnings Release

    Benzinga
  30. Health Care Sector Wrap

    FoxBusiness
  31. Benzinga's Top Pre-Market Gainers

    Benzinga
  32. A Peek Into The Market Before The Trading Starts

    Benzinga
  33. ImmunoGen

    IBD
  34. Health Care Sector Wrap

    FoxBusiness
  35. UPDATE: J.P. Morgan Reiterates Neutral Rating, Raises PT on ImmunoGen

    Benzinga
  36. Infosys Ltd ADR, Kroger Among Stocks Down on High Volume Thursday

    FoxBusiness
  37. Benzinga's Top Pre-Market Losers

    Benzinga
  38. ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and ...

    Benzinga
  39. Benzinga's Initiation Summary for June 14, 2012

    Benzinga
  40. UPDATE: Cantor Fitzgerald Initiates Hold, $15 PT on ImmmunoGen; In Need ...

    Benzinga
  41. From Earlier: ImmunoGen Announces Development of Trastuzumab Emtansine ...

    Benzinga
  42. From Earlier: ImmunoGen Announces Results from Trastuzumab Emtansine (T-DM1) ...

    Benzinga
  43. Stocks Set to Close Quarter on High Note with Finish Line (FINL) and Research ...

    MarketIntelligenceCenter
  44. ImmunoGen Inc. Reports Operating Results (10-Q)

    GuruFocus
  45. ImmunoGen Up 7% After Earnings Beat

    Benzinga
  46. ImmunoGen

    IBD
  47. Best Biotech Stocks of 2011

    Benzinga
  48. Lilly backs Immunogen tech

    IBD
Trading Center